EMA Recommends Approval of Two Biosimilars
The agency recommended approval of a total of eight drugs at its January 2017 meeting, two of which are biosimilars.
The European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) recommended eight drugs for market authorization at its latest meeting, held Jan. 23–26, 2017. Among the approvals were two biosimilars for the treatment of rheumatoid arthritis.
Several of the recommendations were for treatments of various forms of arthritis:
- Xeljanz (tofacitinib) for the treatment of rheumatoid arthritis
- Amgevita (adalimumab), a biosimilar, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, pediatric Crohn's disease, ulcerative colitis and uveitis
- Solymbic (adalimumab), a biosimilar, for the treatment of rheumatoid arthritis, enthesitis-related arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and uveitis.
- Jylamvo (methotrexate), a hybrid, for the treatment of rheumatological disorders and psoriasis. It was also approved for the maintenance treatment of acute lymphoblastic leukaemia (ALL).
CHMP also recommended Yargesa (miglustat) and Daptomycin Hospira (daptomycin), both generics. Yargesa treats Gaucher disease, and Daptomycin Hospira is a treatment for complicated skin and soft-tissue infections (cSSTI), right-sided infective endocarditis (RIE) due to Staphylococcus aureus and S. aureus bacteraemia associated with RIE or with cSSTI.
Positive opinions were granted for two informed consent applications: Rolufta (umeclidinium) for the treatment of chronic obstructive pulmonary disease (COPD) and Tadalafil Lilly (tadalafil) for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia.
The committee also recommended extensions of indications for Revlimid and Synjardy and withdrew marketing authorization for Zioxtenzo (pegfilgrastim), a biosimliar medicine to treat neutropenia in cancer patients, and Xgeva (denosumab), for the treatment of hypercalcemia of malignancy (high levels of calcium in the blood caused by cancer).
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
